# Peptide-HLA multimer staining

Source: https://onco.cc/terms/peptide-hla-multimer-staining/  
OnCo record `peptide-hla-multimer-staining` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This test labels cells whose receptors bind a particular displayed peptide under the assay conditions. It helps identify a binding population that can then be studied for function.

## Summary

The original peptide-MHC tetramer study made soluble multimeric peptide-display complexes to identify antigen-specific T cells. Binding correlated with cytotoxicity in the tested systems, but those observations are different measurements. The chosen peptide and HLA molecule define which interaction is tested. Detecting multimer-binding cells does not by itself establish natural display of that peptide by a tumor, successful target-cell killing or a clinical treatment effect.

## Fields

- Kind: Term
- Last checked: 2026-11-10
- Also known as: peptide-MHC multimer staining; peptide-HLA tetramer staining; pMHC multimer staining

## Notes

- Method card, what it measures: binding of cells to a specified peptide held by a specified HLA allele, under the staining conditions. How: HLA molecules are assembled with the selected peptide and several copies are attached to a labelled scaffold (a tetramer is one format), cells are exposed and analysed, usually by flow cytometry, with viable-cell and gate selection. Input: blood or tissue cells, where staining uses a defined aliquot and compatibility with later living-cell assays depends on the preparation, and the reagent must match both peptide and allele. Thresholds: gate and positivity rules need background and reagent controls, and no universal percentage shows efficacy. Failure modes: nonspecific binding, weak binding, dead cells, a wrong or poorly formed reagent, chain differences or sampling loss. It cannot tell cytokine response, tumour-cell killing, healthy-tissue specificity or benefit.
- Denominators, fictional arithmetic: 100 stained cells among 10,000 gated CD8 T cells is 1%, and the same 100 among 40,000 viable acquired cells is 0.25%. Both are correct and answer different denominator questions, and neither is a body-wide census or a killing rate. A tetramer-negative result is not a census of every possible relevant receptor, because some receptors bind too weakly for a given staining method, and HLA restriction belongs to the peptide-HLA pair and not the peptide alone.
- What the evidence shows: in the original report, tetramers of HLA-A2 with two HIV-derived peptides or an influenza A matrix peptide bound peptide-specific cytotoxic T cells in vitro and T cells from the blood of HIV-infected people, and binding in general correlated well with cytotoxicity assays (Altman 1996). That is a correlation in those systems and not a rule that binding equals killing for an arbitrary tumour peptide. Tetramers are made by mixing biotinylated MHC with fluorescent streptavidin, and a later method made them with small-molecule fluorophores (Ramachandiran 2007), so reagent preparation is a source of variation. An observed stain shows binding under the tested conditions and does not show natural processing and display of that pair by a tumour.
- Connecting assays is an inference task. A multimer-binding cell with no measured cytokine response need not identify one failed biological step: reagent performance, viability, stimulation, measurement window and each assay's threshold can differ. A cytokine response still does not directly measure target-cell death. Compatible cell sorting and receptor sequencing can connect binding to an operational receptor identity, but natural tumour presentation, recognition and killing remain separate questions to test.
- Avidity describes the combined strength of multiple contacts. Multimerising peptide-HLA ligands can make binding detectable when an individual receptor-ligand contact is weak; the 2021 guidelines also caution that more multimerisation does not always improve detection. The measured output is a gate-defined binding fraction or, with a suitable counting method, a count. Reagent, viability and background controls support that binding measurement, which still requires separate validation before use for treatment selection.

## Sources

- Phenotypic analysis of antigen-specific T lymphocytes.: https://doi.org/10.1126/science.274.5284.94
- Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation.: https://doi.org/10.1016/s0022-1759(03)00265-5
- A robust method for production of MHC tetramers with small molecule fluorophores.: https://doi.org/10.1016/j.jim.2006.08.014
- Cossarizza et al.: flow cytometry and cell sorting guidelines, third edition (2021): https://doi.org/10.1002/eji.202170126

## Connected records

- terms: [Flow cytometry (immunophenotyping)](https://onco.cc/terms/flow-cytometry/), [Immune measurements and product evidence](https://onco.cc/terms/immune-product-evidence/), [Immune-cell cytotoxicity assays](https://onco.cc/terms/immune-cytotoxicity-assays/), [Intracellular cytokine staining](https://onco.cc/terms/intracellular-cytokine-staining/), [Peptide binding, presentation and immune recognition](https://onco.cc/terms/binding-presentation-recognition/), [T-cell receptor repertoire sequencing](https://onco.cc/terms/tcr-repertoire-sequencing/)

---
JSON: https://onco.cc/api/v1/entities/peptide-hla-multimer-staining.json